Bo Dai
6PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Feb 06, 2026
Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.Junhong Li, Zhe Hong, Junyu Zhang
|Jul 17, 2025
Early clinical experience with the Carina robotic platform in urologic surgery.Hongkai Wang, Dalong Cao, Marcio Covas Moschovas
|Jan 19, 2024
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.Junhong Li, Zhe Hong, Junyu Zhang
|Dec 11, 2023
A deep learning model, NAFNet, predicts adverse pathology and recurrence in prostate cancer using MRIs.Wei-Jie Gu, Zheng Liu, Yun-Jie Yang
|Feb 01, 2022
Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.Yunjie Yang, Zheng Liu, Qifeng Wang
|Dec 12, 2018
Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.Yun-Jie Yang, Yun-Yi Kong, Gao-Xiang Li
Pageof 1
